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Background: Identification of pregnant women susceptible to rubella is important as vaccination can be given
postpartum to prevent future risks of congenital rubella syndrome. However, in Malaysia, rubella antibody screening
is not offered routinely to pregnant women in public funded health clinics due to cost constraint. Instead, a history
of rubella vaccination is asked to be provided to establish the women’s risk for rubella infection. The usefulness of
this history, however, is not established. Thus, this paper aimed to determine the usefulness of a history of rubella
vaccination in determining rubella susceptibility in pregnant women.
Methods: A cross-sectional study was conducted on 500 pregnant women attending a public funded health clinic.
Face-to-face interviews were conducted, and demographic data and history of rubella vaccination were obtained.
Anti-rubella IgG test was performed.
Results: A majority of the women (66.6%) had a positive vaccination history. Of these, 92.2% women were immune.
A third (33.4%) of the women had a negative or unknown vaccination history, but 81.4% of them were immune to
rubella. The sensitivity and specificity of a history of rubella vaccination in identifying disease susceptibility was
54.4% (95% CI: 40.7, 67.4%) and 69.3% (95% CI: 64.7, 73.5%) respectively; the positive predictive value was 18.6%
(95% CI: 13.1, 25.5%) and the negative predictive value was 92.2% (95% CI: 88.6, 94.7%).
Conclusions: A vaccination history of rubella had a poor diagnostic value in predicting rubella susceptibility.
However, obtaining a vaccination history is inexpensive compared with performing a serological test. A cost-utility
analysis would be useful in determining which test (history versus serological test) is more cost-effective in a
country with resource constraint.
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Rubella infection is a mild disease when it affects
children. However, when it affects pregnant women in
the early trimester, it can cause serious complications
such as miscarriage to the mother and congenital rubella
syndrome (CRS) to the fetus [1,2]. CRS is an important
cause of severe birth defects with ophthalmic, auditory,
cardiac and neurological abnormalities.* Correspondence: caitheng@gmail.com
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reproduction in any medium, provided the orAlthough some women may acquire natural immunity
against rubella by virtue of being infected in childhood,
which is often asymptomatic [3], it is still important to
vaccinate susceptible women as CRS carries serious
consequences.
Cutts et al. (1999) estimated a total of 110,000 CRS
cases in the developing countries [4]. The incidence rate
of CRS in developing countries ranged from 0.4 to 4.3 per
1000 live births [5]. In Malaysia, a retrospective review of
rubella serology from 1993–1998 at University Hospital,
Kuala Lumpur had reported an incidence rate of 0.5 per
1000 live births for CRS [5,6]. In recent years, sporadicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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although the exact number is unknown.
One of the ways to reduce CRS is to vaccinate all
women before they reach reproductive age. The World
Health Organization (WHO) has reported that 131 out
of 193 WHO member countries (68%) have included ru-
bella vaccination in their national immunization sched-
ule [9]. Malaysia started the rubella vaccination program
in 1988 targeting school girls aged 12 to 15 years, and
women in the reproductive age group (15 – 44 years)
[10]. Since 2002, the program has replaced rubella
vaccine with the 2-dose measles-mumps-rubella (MMR)
vaccination for all children aged 1 and 7 years [11]. In
2011, the uptake of the MMR vaccination for children
aged 1 to 2 years was about 95% [12]. Despite the
vaccination program, outbreak of rubella has been
reported among 16-year old students in a military voca-
tional training school in 2006 [13] and the prevalence of
rubella susceptibility in pregnant women has been
reported to range between 8% and 11% in Malaysia
[14,15]. This prevalence is relatively high compared with
some countries in the Asia-pacific region such as
Australia (2.7%) [16] and Japan (6.7%) [17], but is lower
than Singapore (15.8%), Thailand (18.0%), Taiwan
(16.7%) and Sri Lanka (24%) [18-21]. Therefore, efforts
are still needed to reduce rubella susceptibility among
pregnant women.
To achieve a reduction in rubella susceptibility in
women, apart from implementing rubella vaccination as
part of the childhood immunization schedule, supple-
mentary vaccination can be employed as an additional
strategy [22]. In some countries, screening for rubella
antibodies is carried out during antenatal period to iden-
tify susceptible women who are then vaccinated post
partum [22-24]. In Malaysia, rubella antibody is not rou-
tinely screened for in pregnant women in public funded
health clinics due to cost constraint. Instead, these
women are routinely asked for a history of rubella vac-
cination to identify their risk for rubella infection as
some studies have shown that rubella vaccination status
is significantly associated with susceptibility to rubella
infection [20,21]. Women who have no history of rubella
vaccination are then offered the vaccination post par-
tum. The aim of this study was thus to determine the
usefulness of a history of rubella vaccination as a scree-
ning tool for rubella susceptibility in countries such as
Malaysia that do not offer routine antenatal rubella anti-
body screening.
Methods
Study design and participants
A cross-sectional study was carried out at a public
funded health clinic from June to October 2005 in the
state of Selangor, Malaysia. All pregnant women aged 15to 45 years attending the clinic for antenatal booking were
invited to participate in the study. Women with symptoms
of possible acute rubella infection as signified by fever and
rash were excluded from the study. Pregnant women who
consented to the study were recruited. For women aged
less than 18 years, written consents were taken from both
the women and their guardians. The study was approved
by the Medical Ethics Committee of University Malaya
Medical Centre and the Ministry of Health, Malaysia.
Setting
Malaysia is a multiracial country with a population of
28.3 million according to the population census of 2010.
The ethnic distribution consists of 67.4% Malay, 24.6%
Chinese, 7.3% Indian and 0.7% others [25]. Selangor is
the most densely populated among the fourteen states of
the country. It has a population of 5.46 million and is
highly urbanized. The health clinic in this study served a
population of 67,578 [25]. It has a maternal and child
health clinic that provides free service to Malaysian citi-
zens. The ethnic distribution of this study-population of
female aged 15–45 years was similar to the Selangor and
Malaysian census [25,26].
Data collection
Face-to-face interviews were conducted using structured
data collection forms to obtain socio-demographic data,
history of rubella vaccination and past history of rubella
infection. (Additional file 1). For history of rubella vacci-
nation, the following question was asked: “Have you ever
been vaccinated for rubella?” There were three options
for response: “yes”, “no” or “don’t know”. Those who
answered “no” or “don’t know” were considered suscep-
tible to rubella infection. The history of rubella vaccin-
ation was self reported as there was no documentation of
vaccination available for verification. The women were
also asked for past history of rubella infection. Those who
answered yes were asked if they had the diagnosis verified
either by a doctor or by a blood test.
All recruited women then had their serum IgG rubella
antibody level measured, and this level was used as the gold
standard for rubella susceptibility. The IgG rubella antibody
was measured using the AxSYM Rubella IgG assay based
on the Microparticle Enzyme Immunoassay (MEIA) tech-
nology. A rubella IgG antibody level of 10 IU/mL or greater
indicates immunity to rubella infection either through
previous rubella infection or induced by previous vaccine.
A rubella IgG antibody level of less than 10 IU/mL is consi-
dered susceptible to rubella infection.
Sample size
Using epi-info version 6.0, the sample size was calcu-
lated based on the expected prevalence of rubella
susceptibility of 8% and the worst acceptable prevalence
Table 2 Sensitivity, specificity, positive and negative












No history of vaccination or
unknown vaccination status
( rubella susceptible)




26 (7.8%) 307 (92.2%) 333
(100%)
Total 57 443 500
Sensitivity of rubella vaccination history for rubella susceptibility= 31/ (31+26 )
x 100 = 54.4% (95% CI: 40.7, 67.4%).
Specificity of rubella vaccination history for rubella susceptibility= 307/ (307
+136) x 100 = 69.3% (95% CI: 64.7, 73.5%).
Positive predictive value of rubella vaccination history = 31/ (31+136) x 100 =
18.6% (95% CI: 13.1, 25.5%).
Negative predictive value of rubella vaccination history = 307/ (307+26) x 100
= 92.2% (95% CI: 88.6, 94.7%).
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sample size was 314.
Statistical analysis
Data were analyzed using SPSS version 15. Sensitivity
and specificity, the positive and negative predictive
values of a history of rubella vaccination in identifying
rubella susceptibility were determined using anti-rubella
IgG level as the gold standard. In this study, the “test”
was a “history of rubella vaccination”. The aim of the
“test” was to correctly identify women who were suscep-
tible to rubella. The gold standard for rubella suscep-
tibility was those with anti-rubella IgG<10 IU/mL.
Sensitivity of the test is defined as the percentage of all
susceptible women who indeed reported to be not vacci-
nated or to be unknown whether vaccinated. Specificity
is defined as the percentage of all protected women that
indeed reported to be vaccinated. Positive predictive
value of the test is the chance that a woman who
reported to be not vaccinated was susceptible to rubella.
Results
Five hundred and two (502) patients who satisfied the
inclusion criteria were approached. Two patients refused
to participate. The response rate was 99.6%. A majority of
women were Malay (55.2%), followed by Chinese (23.0%),
Indian (8.6%) and others (13.2%). The age ranged from 16
to 42 years, the mean age being 27.2 (SD 4.8) years; the
median age was 27.0 years (IQR 6.0). Half the women were
primigravida (49.2%). None of them reported a past history
of rubella infection that was confirmed by clinical diagnosis
of a physician or by blood test. The prevalence of rubella
susceptibility in this study was 11.4% [95% CI: 8.6, 14.2%].
Most of the women (66.6%) had a positive vaccination
history. Of these, 92.2% were immune. (Table 1) A third
(33.4%) of the women had a negative vaccination history
(no history of previous vaccination or unknown vaccin-
ation status); nevertheless, 81.4% of them were immune
to rubella. (Table 2) A history of rubella vaccination
was significantly associated with rubella susceptibility


















22 (33.3) 44 (66.7) 66 (100.0)
Unknown
vaccination status
9 (8.9) 92 (91.1) 101 (100.0)
Vaccinated 26 (7.8) 307 (92.2) 333 (100.0)our previous analysis have shown that a negative vacci-
nation history was a significant predictor for rubella
susceptibility (odd ratio=2.7, 95% CI: 1.5, 4.7) after con-
trolling for age, ethnicity, parity, education level and
occupation [15].
The sensitivity of a history of rubella vaccination in iden-
tifying rubella susceptibility using serological test as gold
standard was 54.4% (95% CI: 40.7, 67.4%) and the specificity
was 69.3% (95% CI: 64.7, 73.5%). The positive predictive
value was 18.6% (95% CI: 13.1, 25.5%) and the negative
predictive value was 92.2% (95% CI: 88.6, 94.7%) (Table 2).
Discussion
The aim of the test (vaccination history) was to identify
women susceptible to rubella in order to offer them
vaccination to prevent rubella in future pregnancies. For
this purpose, sensitivity is the most important element
of the test. The sensitivity of the test was 54%. Hence,
on the basis of just a history of rubella vaccination,
almost half the susceptible women would be overlooked
and remain unprotected against rubella. On the other
hand, compared with no serological testing at all, a nega-
tive vaccination history would at least identify half of the
susceptible women. The specificity of the test was 69%;
however, it is not a clinical problem that 31% of the
women were protected while they reported to be not
vaccinated. This could be due to natural immunity they
acquired during childhood subclinical infection that
often goes unnoticed. The positive predictive value of
the test is only 19%, which means that there is a one in
five chance that a woman who reported to be not vacci-
nated was susceptible to rubella, the majority being pro-
tected. The negative predictive value was 92%, which
means that the majority of women who reported positive
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sensitivity and positive predictive value of the rubella
vaccination history might not be useful in screening for
rubella-susceptible women. Serological testing, the gold
standard test, is superior in correctly identifying women
who are susceptible to rubella. Nonetheless, serological
test is expensive compared with an enquiry of vacci-
nation history. A cost-utility analysis is needed to deter-
mine which test is preferable from a public health point
of view: a history of vaccination “test” or a serological
test, especially for a resource constrained country.
7.8% of the women who reported having had vacci-
nation were found to have low antibody titer level and
were considered to be not protected based on the cut-off
level of anti-rubella IgG of 10 IU/mL. This proportion is
substantial given the serious complications resulting from
congenital rubella syndrome. Therefore, screening for
rubella susceptibility using a history of rubella vaccination
would have overlooked this group of women and denied
them the benefit of rubella booster dose to prevent con-
genital rubella syndrome. Some studies have reported the
possibility of a gradual decline in the rubella antibody titer
from a protective level to a non-protective level in some
individuals who had the vaccination [27-29]. Therefore, it
is possible for rubella to occur during pregnancy even in
women who have had the vaccination.
About two-third of the women who reported negative
rubella vaccination history had protective antibody titers.
Some of these women may have acquired the immunity
through subclinical infections they were not aware of
when they were young [3]. Some women may have expe-
rienced fever and rash and did not relate it to rubella
infection as these symptoms mimic other common viral
infections. Locally, rubella antibody test is not performed
in women for confirmation of the disease as the disease is
mild and self-limiting, and does not require notification.
In this study, we used anti-rubella IgG level of 10 IU/mL
as the cut-off point for protection against rubella infection.
This was the recommended level based on earlier epi-
demiological studies when rubella infection was prevalent
[30]. Although a recent study on the sero-prevalence of
rubella antibody over time has suggested that the cut-off
level of anti-rubella IgG for protection against infection
should be adjusted according to an immunized antenatal
population rather than following the older recommenda-
tion [30], we lacked local serological data regarding rubella
antibody level for women of childbearing age to ascertain
the level of protection for rubella infection. Until such
data becomes available, the cut-off level of 10 IU/mL
would be used.
The strength of this study was the recruitment of par-
ticipants from a public funded health clinic, which pro-
vided most of the antenatal care for pregnant women in
the country. The study is limited by its cross-sectionaldesign and the socio-economic status of the participants,
who were mainly from the middle and lower socio-
economic groups that may differ from patients seen in
other settings. Therefore, caution is necessary in genera-
lizing the findings. Nevertheless, this study that has pro-
vided us the preliminary evidence of an inexpensive test,
namely, a history of rubella vaccination, is not a useful
screening tool for rubella susceptibility. Further study is
needed to confirm this as it may have implications on
the healthcare policy regarding rubella antibody testing
in pregnant women.
Conclusions
A test based on the history of rubella vaccination has
low sensitivity, specificity and predictive values in deter-
mining rubella susceptibility. Serological testing needs to
be considered in all women of childbearing age to effec-
tively prevent the occurrence of congenital rubella syn-
drome. However, as serology test is more expensive than
taking a vaccination history, a cost-utility analysis is
recommended in case of resource constraint.
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